Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide vs Enzalutamide in Low-volume mHSPC
NCT07241416Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rezvilutamide in prostate cancer (PCa) (2 arms), sponsored by Hengrui. Primary endpoint: Prostate Specific Antigen undetectable rate at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07241416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07241416.